JC-34

JC-34 is a potent, small molecule inhibitor of the gamma-secretase complex, an intramembrane protease responsible for the proteolytic cleavage of various transmembrane proteins, including the Notch receptor and Amyloid Precursor Protein (APP). Developed at the Memorial Sloan-Kettering Cancer Center (MSKCC), JC-34 is primarily used in preclinical research to study the role of Notch signaling in oncogenesis. By inhibiting gamma-secretase, JC-34 prevents the release of the Notch intracellular domain (NICD), which in turn suppresses the transcription of downstream target genes such as Hes1. Research has demonstrated that the therapeutic efficacy of JC-34 in malignancies like melanoma, sarcoma, and breast cancer is highly dependent on the PTEN status of the tumor cells; cells with wild-type PTEN typically exhibit sensitivity through G1 cell cycle arrest and apoptosis, whereas PTEN-deficient cells often show resistance.